NBY

NovaBay Global Ophthalmology Study Enrolls First Patients in Brazil

[at noodls] – Press Releases EMERYVILLE, CA – April 8, 2013 BAYnovation Phase 2b Trial for the Treatment of Viral Conjunctivitis Spans Three Continents NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology … moreView todays social media effects on NBYView the latest stocks trending across Twitter. Click to view dashboardSee who NovaBay is hiring next, click here to view […]

NovaBay Pharmaceuticals Reports Fourth Quarter Financial Results and 2013 Clinical and Business Update

[at noodls] – Well Positioned in 2013 with Three Phase 2b Clinical Trials for Conjunctivitis, Impetigo and UCBE Advancing EMERYVILLE, Calif., March 14, 2013 — NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology … moreView todays social media effects on NBYView the latest stocks trending across Twitter. Click to view dashboardSee who NovaBay is hiring next, click here to view […]

NovaBay Pharmaceuticals to Present at the 25th Annual ROTH Conference

[at noodls] – EMERYVILLE, CA – March 12, 2013 – NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing a large unmet therapeutic needs of the global anti-infective market with … moreView todays social media effects on NBYView the latest stocks trending across Twitter. Click to view dashboardSee who NovaBay is hiring next, click here to view […]

NovaBay Names Keith Bley as Senior Vice President of Product Development

[at noodls] – – Behzad Khosrovi Retires After Ten-Year Career at NovaBay – EMERYVILLE, CA – March 11, 2013 – NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet … moreView todays social media effects on NBYView the latest stocks trending across Twitter. Click to view dashboardSee who NovaBay is hiring next, click here […]

NovaBay Receives Unique Globally Recognized International Nonproprietary Name Auriclosene for NVC-422

[at noodls] – – Data from Three Phase 2 Trials of Lead Aganocide Compound Anticipated in 2013 – – Phase 3 Registration Trials Expected in 2014 – EMERYVILLE, CA – February 20, 2013 – NovaBay® Pharmaceuticals, Inc. (NYSE … moreView todays social media effects on NBYView the latest stocks trending across Twitter. Click to view dashboardSee who NovaBay is hiring […]